Score Overview
Explore the 2021 public Archive ranking →
Where Dr. Reddy’s Laboratories Ltd ADR has ranked, year by year
Showing 10 years ranking history by HDB Score.
Has not reached the top 50 on HDB Score in any year we have ranked.
- RDY
2012: 42.2% · 2020: 30.7% · free through 2021 · longest runs
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-09-29 | $ 12.85 | — |
1 Year2025-09-29 | $ 13.83 | -7.09% |
5 Years2021-09-29 | $ 11.46 | 12.11% |
10 Years2016-09-29 | $ 7.47 | 71.96% |
20 Years2006-09-29 | $ 2.36 | 443.62% |
All Time2001-04-11 | $ 0.72 | 17x |
| Period | Last Price2026-09-29 | 1 Year2025-09-29 | 5 Years2021-09-29 | 10 Years2016-09-29 | 20 Years2006-09-29 | All Time2001-04-11 |
|---|---|---|---|---|---|---|
| Price | $ 12.85 | $ 13.83 | $ 11.46 | $ 7.47 | $ 2.36 | $ 0.72 |
| Return | — | -7.09% | 12.11% | 71.96% | 443.62% | 17x |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
Reported in INR
| Year | |||
|---|---|---|---|
| TTM | ₹ 332.83B | ₹ 33.16B | ₹ 81.42B |
| 2026 | ₹ 353.47B | ₹ 45.08B | ₹ 86.07B |
| 2025 | ₹ 325.53B | ₹ 56.54B | ₹ 57.90B |
| 2024 | ₹ 279.16B | ₹ 55.68B | ₹ 81.47B |
| 2023 | ₹ 245.87B | ₹ 45.06B | ₹ 61.79B |
| 2022 | ₹ 214.39B | ₹ 23.56B | ₹ 44.36B |
| 2021 | ₹ 2.55B | ₹ 472M | |
| 2020 | ₹ 174.60B | ₹ 19.49B | ₹ 340M |
| 2019 | ₹ 153.85B | ₹ 18.79B | ₹ 24.75B |
| 2018 | ₹ 142.02B | ₹ 9.80B | ₹ 20.96B |
| 2017 | ₹ 140.80B | ₹ 12.03B | ₹ 18.13B |
| 2016 | ₹ 154.70B | ₹ 20.01B | ₹ 39.95B |
| 2015 | ₹ 148.18B | ₹ 22.17B | ₹ 39.65B |
| 2014 | ₹ 132.17B | ₹ 21.51B | ₹ 33.53B |
| 2013 | ₹ 116.26B | ₹ 16.77B | ₹ 220.99B |
| 2012 | ₹ 96.73B | ₹ 14.26B | ₹ 18.15B |
| 2011 | ₹ 74.69B | ₹ 11.04B | ₹ 5.76B |
| 2010 | ₹ 70.27B | ₹ 1.06B | ₹ 10.75B |
| 2009 | ₹ 69.44B | -₹ 5.16B | ₹ 6.12B |
| 2008 | ₹ 50.00B | ₹ 4.67B | ₹ 12.15B |
| 2007 | ₹ 65.24B | ₹ 9.34B | ₹ 18.03B |
| 2006 | ₹ 24.32B | ₹ 1.63B | |
| 2005 | ₹ 19.47B | ₹ 211M | ₹ 9.59B |
| 2004 | ₹ 20.12B | ₹ 2.47B | ₹ 6.92B |
| 2003 | ₹ 18.01B | ₹ 3.52B | ₹ 7.25B |
| 2002 | ₹ 16.60B | ₹ 4.91B | ₹ 5.10B |
Dr. Reddy’s Laboratories Ltd ADR fundamental performance
Between 2021 and 2026, revenue grew from ₹ 2.55B to ₹ 353.47B. Revenue increased in 4 of those 5 years; net income in 3.
Across Dr. Reddy’s Laboratories Ltd ADR's full reported history, from 2002 to 2026, revenue grew from ₹ 16.60B to ₹ 353.47B and net income grew from ₹ 4.91B to ₹ 45.08B. Revenue increased in 80% of the years measured; net income in 57%.
Dr. Reddy’s Laboratories Ltd ADR currently holds a 20-year HDB Score of 6.0 out of 10. How the HDB Score is calculated.
Membership
Continue RDY’s history
The public Archive runs through 2021. Membership adds recent and current rankings.
- Recent and current rankings across 3,814 companies
- Compare companies with the latest data
- Track your research shortlist in a portfolio
